



IMPACT REPORT

20 25





Contents

- 3** From Vaccines to Vaccinations
- 4** 2025 at a Glance
- 5** Impact Highlights
- 6** A Year of Progress and Partnership
- 7** Developing Vaccines and Responding to Outbreaks
- 9** Advancing Global Immunization
- 11** Recognizing Vaccine Excellence
- 13** Staff and Board
- 14** Financials
- 15** Future Outlook

Cover Image: A mother and child receive the hexavalent vaccine in Dakar, Senegal.
Credit: Sabin Vaccine Institute

From Vaccines *to Vaccinations*

The Sabin Vaccine Institute is a global health nonprofit working to protect people everywhere from vaccine-preventable diseases. We partner with communities, governments, researchers, industry, and global health organizations to advance the full journey from vaccines to vaccinations — developing vaccines for emerging infectious diseases, strengthening outbreak preparedness and response, generating evidence that informs vaccine policy and delivery, and building confidence in immunization.

By connecting science, policy, and practice, we help ensure vaccines are not only developed, but also trusted, delivered, and accessible to the people who need them most. Together with our partners, we are protecting individuals, building healthier communities, and strengthening global health security.

Our vision is a world free from vaccine-preventable diseases.



2025

AT-A-GLANCE

Every year, Sabin's work spans the vaccines to vaccinations continuum, from developing much-needed vaccines to generating evidence-based strategies that support countries as they work to optimize delivery of vaccines and prevent disease.

In 2025, we achieved major milestones across our areas of work:



In Ethiopia, **we responded to a Marburg virus disease outbreak**, during which our cAd3-Marburg Vaccine was deployed in a clinical trial against the lethal disease.



We advanced our clinical work by **initiating U.S. Phase 2 trials** for both our Marburg and Sudan virus vaccine candidates.



In Kenya, we began evaluating whether extending the interval between oral cholera vaccine doses can provide comparable immune protection to the recommended schedule, potentially giving countries **greater flexibility to use limited vaccines more effectively during outbreaks**.



We expanded Sabin's evidence-to-action partnerships across Africa, Latin America, and Asia through collaborative research and regional learning, **generating data that strengthens vaccine policy**, introduction, and immunization planning.

A Year of...

GROWTH & ACCOMPLISHMENT



2

VACCINES

in development against
Marburg and **Sudan**
virus disease



2,800

PARTICIPANTS

enrolled in clinical trials



3

OUTBREAK RESPONSES

for Marburg and Sudan
virus disease outbreaks



6

PHASE 2 CLINICAL TRIALS

in **5 countries**: Kenya, Uganda,
Rwanda, Ethiopia, and U.S.



5,400+

IMMUNIZATION PROFESSIONALS

from nearly **160 countries** engaged in peer-
to-peer learning in the Boost Community



33

COUNTRIES

supported across Africa and Asia
for malaria vaccine introduction
and penta-to-hexa vaccination
switch readiness



115+

INDIVIDUALS

across **17 countries** participated in the
Global HPV Consortium's engagement
series on eliminating cervical cancer in
Latin America

A Year of...

Progress & Partnership



“

Unlike COVID-19, there is no commercial market for a Marburg vaccine. Demand is limited to outbreak response, health workers, and emergency stockpiles. Progress depends almost entirely on public sector and philanthropic investment. Sabin's role is to ensure that lack of commercial viability does not translate into lack of protection.

Amy Finan
Chief Executive Officer

More from Finan on why Sabin's outbreak response efforts and continued development of our cAd3-Marburg vaccine candidate have left us better prepared to meet future challenges — faster, smarter, and together.

[READ MORE](#)



“

When an outbreak begins, as the Marburg outbreak did in Ethiopia late 2025, there is no warm-up period. There's little time to build trust, assemble teams, or figure out who does what. Either science is ready, reputations are established, partnerships are in place, and people know how to move — or you're losing precious opportunity to make a difference.

Kelly Warfield, PhD
President, Research & Development

More from Warfield on how Sabin was tested as we answered Ethiopia's request for help responding to their first Marburg outbreak, and the existing experience we were able to draw upon.

[READ MORE](#)



“

Global health is not standing still — it is rebalancing. If we stay focused on evidence, equity, building trust, and country leadership, this moment of reshaping can be a foundation for a stronger, more resilient immunization ecosystem to protect lives and prevent deaths around the world.

Rebecca Martin, PhD
President, Global Immunization

More from Martin on how Sabin's Global Immunization team is doubling down on cervical cancer elimination, sharing evidence on more effective vaccine rollouts, expanding peer learning, and adapting during a period of uncertainty.

[READ MORE](#)

Developing Vaccines *and Responding to Outbreaks*

Responded to Marburg Outbreak in Ethiopia

Four days after Ethiopia confirmed its first-ever outbreak of Marburg Virus Disease on November 14, 2025, the Ministry of Health contacted Sabin to request investigational cAd3-Marburg Vaccine doses for a clinical trial. Twenty days later, on December 4, **644 doses were delivered to Ethiopia**, and a two-cohort Phase 2 outbreak clinical trial sponsored by the Ministry of Health and conducted by the Armauer Hansen Research Institute began at three health care facilities.

Building on experience gained responding to a Marburg outbreak in Rwanda in 2024, Sabin moved quickly, connecting again with critical partners. “When Ethiopia’s Minister of Health called, we had an informal playbook to start,” says President of R&D Kelly Warfield. The challenges of Ethiopia, more than 40 times the size of Rwanda, required innovations as well, including setting up mobile sites hundreds of miles from Ethiopia’s capital and delivering doses to remote areas.

“These opportunities are rare,” Warfield says. “You cannot recreate the complexity of an outbreak in a laboratory. By embedding rigorous science into real-world response efforts — under strong ethical and regulatory oversight — we can help build the evidence needed to strengthen future outbreak preparedness.”





Advanced Two Filovirus Vaccine Candidates to Phase 2 Clinical Trials

With our mission to improve the lives of people in resource-constrained settings, Sabin's R&D strategy focuses on developing promising vaccine candidates for high-fatality pathogens often overlooked by traditional developers due to their limited commercial viability. Sabin is currently advancing two clinical-stage filovirus candidates toward licensure — one for Marburg virus and one for Sudan virus. Both candidates are built on the cAd3 — chimpanzee adenovirus serotype 3 — platform technology.

In 2025, Sabin launched multi-site U.S. Phase 2 trials for both its cAd3-Marburg (April) and cAd3-Sudan (June) vaccine candidates. Running concurrently with Phase 2 trials in Kenya and Uganda, these U.S. studies evaluate safety, immunogenicity, and dosing across diverse populations.

"Conducting clinical trials in Africa is key to evaluating the vaccine in regions where Marburg and other filoviruses are endemic," says Warfield, adding that the U.S. trial will give Sabin vital safety and immune response data for non-endemic populations, helping us to better prepare for outbreaks and spread of this disease, and to ensure we have data to support U.S. FDA licensure.

Sustained Investment and Institutional Growth

Development of our cAd3 vaccine candidates is supported by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human services. BARDA-funded activities* include manufacturing, preclinical studies, and clinical trials — all needed to advance our vaccines toward licensure.

To keep pace with our development success, Sabin tripled the size of its R&D team in 2025 (going from 12 to 32 employees), bringing in world-class scientific, regulatory, and operational talent — growth that continues to accelerate into 2026. At the same time, Sabin experts elevated the organization's global profile by publishing data and findings in major journals, as well as presenting at international health conferences, cementing Sabin's position as an authoritative voice and trusted leader in filovirus research.

*BARDA Contracts: 75A05119C00055 and 75A50123C00010



Advancing *Global Immunization*

New Leadership and New Strategic Direction

Amid significant shifts in global health, Sabin responded by sharpening its strategy and positioning Global Immunization for the future. Veteran global health leader **Dr. Rebecca Martin joined Sabin as President of Global Immunization**. Drawing on more than two decades of leadership across U.S. Centers for Disease Control & Prevention, World Health Organization, and Emory University, she is guiding a new strategic direction focused on resilient immunization programs amid climate and health security threats, equitable and sustainable access, vaccine confidence and community resilience, and evidence-informed vaccine policy and decision-making.

Connected Global Scientists, Advocates, and Practitioners to Accelerate Collective Action

Sabin continued to bring together the people and expertise needed to turn evidence into action.

- The Global HPV Consortium, led by Sabin, grew to 60 partner organizations in 2025, uniting scientific evidence, advocacy, and community voices to accelerate cervical cancer elimination and address the stigma surrounding HPV. Although cervical cancer is largely preventable and highly treatable when detected early, it still **claims more than 350,000 women's lives each year**, with the greatest burden in low- and middle-income countries. From recognizing student nurse advocates through the Nursing Now Challenge to convening Breaking the Silence Can Break the Stigma at the 2025 International Papillomavirus Society Conference, the Consortium highlighted a fundamental lesson: ending HPV-related cancers requires scientific rigor matched by community trust.

- Sabin brought together **more than 250 global experts** in South Africa for the 15th International Rotavirus Symposium, celebrating two decades of vaccine progress and advancing strategies to integrate rotavirus prevention into child health programs. Pioneers such as Dr. Roger Glass, Professor Julie Bines, Dr. George Armah, and Dr. David Bernstein were honored at the symposium. With rotavirus still **causing an estimated 150,000 to 200,000 deaths among children under five globally**, equitable vaccine access remains critical.
- On the frontlines of immunization, Sabin's Boost Community **connected more than 5,000 immunization professionals** through **more than 30 specialized webinars**. Through peer-to-peer learning on closing coverage gaps, strengthening vaccine confidence, and advancing women's leadership in immunization, practitioners gained actionable knowledge and tools to strengthen programs and address challenges in their own settings.

Optimized Oral Cholera Vaccine Schedules for Maximum Protection

Kenya faces periodic cholera outbreaks driven by seasonal heavy rains, flooding, and limited access to safe drinking water and proper sanitation. As the country considers oral cholera vaccine introduction, Sabin and the Kenya Medical Research Institute (KEMRI) are evaluating whether longer intervals between doses can maintain protection, potentially enabling more flexible vaccine use during outbreaks and in high-risk areas. With KEMRI, Sabin launched a Phase IV vaccine clinical trial in Mukuru, Kenya with the goal of enrolling 800 participants. The study will continue through early 2028.

Built the Future of Immunization Systems: Transition to Hexavalent

The hexavalent vaccine protects against six diseases in one shot (diphtheria, tetanus, pertussis, Hib, hepatitis B and polio) while simplifying immunization delivery and improving uptake. In 2025 and through **HeVAC (Hexavalent Vaccine (Switch) Assessment) Consortium**, Sabin supported 10 African countries in making the switch from pentavalent + polio vaccine to the hexavalent vaccine. A workshop in Senegal brought together these early adopter countries to discuss implementation lessons, sharing what worked well and what challenges may arise. The evidence generated at this meeting was subsequently published in *Vaccine*, with over 30 country co-authors.



The Albert B. Sabin Gold Medal is Sabin's highest scientific honor, awarded since 1994 to distinguished members of the global health community for making exceptional contributions to vaccinology or a complementary field.



Recognizing Vaccine Excellence:

The 2025 Sabin Awards

The Albert B. Sabin Gold Medal

Katherine O'Brien

Our 2025 Gold Medal winner, **Dr. Katherine O'Brien**, is a pioneering global health leader whose groundbreaking work in vaccine access and policy has transformed immunization programs worldwide. As Director, Immunization, Vaccines and Biologicals for the World Health Organization, O'Brien leads the global strategy to inform global vaccine policy, accelerate vaccine research, strengthen immunization programs, and advance vaccine equity.

O'Brien's leadership has left an indelible mark on the global immunization landscape. Her tireless advocacy for vaccine equity has strengthened immunization programs, shaped international health policy, saved lives, and improved the health of populations across generations.

[READ MORE](#)

Established in 2020, the Sabin Rising Star recognizes and highlights the work of emerging vaccine leaders under the age of 40.

The Sabin Rising Star

Livancliff Mbianke

Our 2025 Rising Star, Dr. Livancliff Mbianke, is a dedicated physician and public health specialist whose work in vaccine access and strengthening health systems has made a profound impact on underserved communities. With expertise in immunization, maternal and child health, and community engagement, Mbianke has played a pivotal role in expanding vaccine coverage and improving health outcomes in fragile settings.

A Rising Star in global health, Mbianke continues to push the boundaries of innovation in vaccine delivery and policy.

[READ MORE](#)



2025 Staff and Board

EXECUTIVE STAFF

Amy Finan
Chief Executive Officer

Rebecca Martin, PhD
President, Global
Immunization

Kiju deLeon, CPA
Chief Financial Officer

Kelly Warfield, PhD
President, Research &
Development

BOARD OF TRUSTEES

**As of December 2025*

Regina Rabinovich, MD, MPH
Chair
Executive Committee Chair
Governance Committee Chair

Richard A. Adegbola, PhD,
FIMLS, FRCPPath, FRCP (Hon),
FAS

Norman Baylor, PhD
Vice Chair

Yacine Djibo, MBA

Filip Dubovsky, MD, MPH

Amy Finan
Chief Executive Officer

Elizabeth Fox, PhD

Axel Hoos, MD, PhD

Orin Levine, PhD

Jeffrey P. Libson, JD
Secretary

David Salisbury, CB,
FMedSci, FRCP, FRCPCH,
FFPH
Global Immunization Chair

Jacqueline Shea, PhD
Treasurer and Finance & Audit
Committee Chair

JoAnn Suzich, PhD
R&D Committee Chair

Nadia Tornieporth, MD



Financials

How We Used Our Funds in 2025

- **92%**
\$55,774,920
on programs
- **8%**
\$4,780,736
on organizational
management &
administration
- **<1%**
\$55,131
on resource
development &
fundraising to support
future growth



Program Expenditures in 2025

- **85%**
\$46,500,242
on vaccine research
& development
- **15%**
\$8,274,678
on global
immunization





A Look Ahead:


Vaccines, Preparedness, and the Future of Global Health Security

Global health is entering a new era. Disease threats are increasingly shaped by conflict and instability, strained health systems, shifting funding priorities, misinformation, and declining public trust. From outbreaks in conflict-affected settings to emerging infectious diseases and growing vaccine skepticism, one lesson is clear: **preparedness is fundamental to global health security.** So too is the ability to detect threats early, respond rapidly, and ensure effective interventions reach the people who need them.

Sabin is uniquely positioned to contribute through our “**vaccines to vaccinations**” approach. We understand that developing or deploying a vaccine is only the beginning. Turning vaccines into protection requires evidence, strong delivery systems, effective policies, country leadership, trained health workers, community engagement, and public trust. By connecting vaccine science and development with the realities of immunization, Sabin helps bridge the gap between what is possible in the laboratory and what is achievable in communities.

Looking ahead, Sabin will build on its expertise across research and development, immunization, vaccine confidence, and health security to help countries prepare for and respond to evolving infectious disease threats. We will support the development and evaluation of vaccines against emerging pathogens while strengthening the evidence, systems, partnerships, and policies needed to turn vaccines into protection. Our experience in outbreak settings demonstrates the value of being ready before a crisis escalates.

The next era of global health security will demand more than vaccines in the pipeline. It will require the capacity to move from scientific innovation to trusted, effective vaccination – quickly and equitably. Sabin’s vaccines-to-vaccinations approach positions us to help shape that future: a world better prepared for emerging threats, better equipped to respond, and better able to turn vaccines into lasting protection.



2000 Pennsylvania Ave, NW, Suite 7000
Washington, DC 20006

+1 202 842 5025

info@sabin.org

www.sabin.org

